|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/14/18 Biolase, Inc 10-K 12/31/17 82:13M ActiveDisclosure/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 1.19M
2: EX-4.4 Instrument Defining the Rights of Security Holders HTML 64K
3: EX-10.26 Material Contract HTML 172K
4: EX-10.27 Material Contract HTML 155K
5: EX-10.28 Material Contract HTML 149K
6: EX-10.29 Material Contract HTML 142K
7: EX-21.1 Subsidiaries List HTML 21K
8: EX-23.1 Consent of Experts or Counsel HTML 25K
9: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
10: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
11: EX-32.1 Certification -- §906 - SOA'02 HTML 25K
12: EX-32.2 Certification -- §906 - SOA'02 HTML 25K
19: R1 Document and Entity Information HTML 53K
20: R2 Consolidated Balance Sheets HTML 110K
21: R3 Consolidated Balance Sheets (Parenthetical) HTML 44K
22: R4 Consolidated Statements Of Operations And HTML 98K
Comprehensive Loss
23: R5 Consolidated Statements Of Shareholders' Equity HTML 85K
24: R6 Consolidated Statements Of Shareholders' Equity HTML 25K
(Parenthetical)
25: R7 Consolidated Statements Of Cash Flows HTML 119K
26: R8 Basis of Presentation HTML 49K
27: R9 Summary of Significant Accounting Policies HTML 166K
28: R10 Supplementary Balance Sheet Information HTML 183K
29: R11 Intangible Assets and Goodwill HTML 74K
30: R12 Income Taxes HTML 218K
31: R13 Commitments and Contingencies HTML 48K
32: R14 Stockholders' Equity HTML 397K
33: R15 Segment Information HTML 69K
34: R16 Concentrations HTML 89K
35: R17 Subsequent Events (Unaudited) HTML 32K
36: R18 Schedule II-Consolidated Valuation and Qualifying HTML 117K
Accounts and Reserves
37: R19 Summary of Significant Accounting Policies HTML 264K
(Policies)
38: R20 Summary of Significant Accounting Policies HTML 126K
(Tables)
39: R21 Supplementary Balance Sheet Information (Tables) HTML 192K
40: R22 Intangible Assets and Goodwill (Tables) HTML 68K
41: R23 Income Taxes (Tables) HTML 217K
42: R24 Commitments and Contingencies (Tables) HTML 37K
43: R25 Stockholders' Equity (Tables) HTML 353K
44: R26 Segment Information (Tables) HTML 70K
45: R27 Concentrations (Tables) HTML 89K
46: R28 Basis of Presentation - Additional Information HTML 113K
(Detail)
47: R29 Summary of Significant Accounting Policies - HTML 74K
Additional Information (Detail)
48: R30 Estimated Useful Lives of Property, Plant and HTML 37K
Equipment (Detail)
49: R31 Changes in Initial Product Warranty Accrual and HTML 38K
Expenses Under Initial and Extended Warranties
(Detail)
50: R32 Classification of Compensation Expense Associated HTML 37K
with Share-Based Payments (Detail)
51: R33 Assumptions Used in Estimating Fair Value of Stock HTML 33K
Options Granted (Detail)
52: R34 Components of Accounts Receivable, Net of HTML 32K
Allowance (Detail)
53: R35 Supplementary Balance Sheet Information - HTML 41K
Additional Information (Detail)
54: R36 Components of Inventory (Detail) HTML 33K
55: R37 Summary of Property, Plant, and Equipment (Detail) HTML 50K
56: R38 Components of Accrued Liabilities (Detail) HTML 46K
57: R39 Summary of Deferred Revenue (Detail) HTML 45K
58: R40 Intangible Assets and Goodwill - Additional HTML 32K
Information (Detail)
59: R41 Intangible Assets and Related Accumulated HTML 50K
Amortization (Detail)
60: R42 Summary of Income Tax Current and Deferred HTML 43K
Provision (Detail)
61: R43 Federal Income Tax Provision Compared With HTML 51K
Statutory Rates (Detail)
62: R44 Summary of Net Deferred Tax Assets and Net HTML 72K
Deferred Tax Liabilities (Detail)
63: R45 Income Taxes - Additional Information (Detail) HTML 73K
64: R46 Summary of Unrecognized Tax Benefits (Detail) HTML 30K
65: R47 Commitments and Contingencies - Additional HTML 60K
Information (Detail)
66: R48 Future Minimum Rental Commitments Under Lease HTML 36K
Agreements (Detail)
67: R49 Stockholders' Equity - Additional Information HTML 810K
(Detail)
68: R50 Summary of Warrant Activity (Detail) HTML 57K
69: R51 Summary of Option Activity (Detail) HTML 70K
70: R52 Options Outstanding and Exercisable (Detail) HTML 65K
71: R53 Cash Proceeds Along with Fair Value Disclosures HTML 35K
Related to Grants, Exercises, and Vesting Options
(Detail)
72: R54 Summary of Unvested Restricted Stock Units HTML 36K
(Detail)
73: R55 Segment Information - Additional Information HTML 37K
(Detail)
74: R56 Summary of Net Revenue by Geographic Location HTML 30K
(Detail)
75: R57 Summary of Long-Lived Assets by Geographic HTML 32K
Location (Detail)
76: R58 Concentrations - Summary of Net Revenue from HTML 49K
Various Products (Detail)
77: R59 Concentrations - Additional Information (Detail) HTML 31K
78: R60 Subsequent Events (unaudited) - Additional HTML 101K
Information (Detail)
79: R61 Consolidated Valuation and Qualifying Accounts and HTML 38K
Reserves (Detail)
81: XML IDEA XML File -- Filing Summary XML 136K
80: EXCEL IDEA Workbook of Financial Reports XLSX 103K
13: EX-101.INS XBRL Instance -- biol-20171231 XML 3.68M
15: EX-101.CAL XBRL Calculations -- biol-20171231_cal XML 203K
16: EX-101.DEF XBRL Definitions -- biol-20171231_def XML 699K
17: EX-101.LAB XBRL Labels -- biol-20171231_lab XML 1.56M
18: EX-101.PRE XBRL Presentations -- biol-20171231_pre XML 1.15M
14: EX-101.SCH XBRL Schema -- biol-20171231 XSD 227K
82: ZIP XBRL Zipped Folder -- 0001564590-18-005648-xbrl Zip 223K
Exhibit 32.2
CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. § 1350
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of BIOLASE, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2017, (the “Report”), I, John R. Beaver, Senior Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
(i) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: March 14, 2018 |
|
By:/s/ JOHN R. BEAVER |
|
|
|
|
|
|
|
Senior Vice President and Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/14/18 | 8-K | ||
| For Period end: | 12/31/17 | SD | ||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/10/21 Biolase, Inc. 10-Q 9/30/21 84:13M Donnelley … Solutions/FA 8/13/21 Biolase, Inc. 10-Q 6/30/21 80:12M Donnelley … Solutions/FA 5/13/21 Biolase, Inc. 10-Q 3/31/21 81:9.4M Donnelley … Solutions/FA 3/31/21 Biolase, Inc. 10-K 12/31/20 88:15M ActiveDisclosure/FA 12/08/20 Biolase, Inc. S-1/A 3:585K Donnelley … Solutions/FA 11/13/20 Biolase, Inc. 10-Q 9/30/20 81:11M ActiveDisclosure/FA 8/14/20 Biolase, Inc. 10-Q 6/30/20 89:12M ActiveDisclosure/FA |